Description
Storage
Supplied in PBS (pH 7.2), 2 mM EDTA, 0.05% Triton X-100, 2 mg/mL BSA, and 50% glycerol. Store at -20°C. Do not aliquot the antibody.
Protocol
Available protocols: Single Cell Analysis - InTraSeq™ 3'
Specificity / Sensitivity
Phospho-p38 MAPK (Thr180/Tyr182) (D3F9) Rabbit Monoclonal Antibody (InTraSeq™ 3' Conjugate 3077) detects endogenous levels of p38 MAPK only when phosphorylated at Thr180 and Tyr182. This antibody conjugate does not cross-react with the phosphorylated forms of either p42/44 MAPK or SAPK/JNK.
Species Reactivity: Human, Mouse
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic phosphopeptide corresponding to residues surrounding Thr180/Tyr182 of human p38 MAPK.
Background
p38 MAP kinase (MAPK), also called RK (1) or CSBP (2), is the mammalian orthologue of the yeast HOG kinase that participates in a signaling cascade controlling cellular responses to cytokines and stress (1-4). Four isoforms of p38 MAPK, p38α, β, γ (also known as Erk6 or SAPK3), and δ (also known as SAPK4) have been identified. Similar to the SAPK/JNK pathway, p38 MAPK is activated by a variety of cellular stresses, including osmotic shock, inflammatory cytokines, lipopolysaccharide (LPS), UV light, and growth factors (1-5). MKK3, MKK6, and SEK activate p38 MAPK by phosphorylation at Thr180 and Tyr182. Activated p38 MAPK has been shown to phosphorylate and activate MAPKAP kinase 2 (3) and to phosphorylate the transcription factors ATF-2 (5), Max (6), and MEF2 (5-8). SB203580 (4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)-imidazole) is a selective inhibitor of p38 MAPK. This compound inhibits the activation of MAPKAPK-2 by p38 MAPK and subsequent phosphorylation of HSP27 (9). SB203580 inhibits p38 MAPK catalytic activity by binding to the ATP-binding pocket, but does not inhibit phosphorylation of p38 MAPK by upstream kinases (10).
Alternate Names
CSAID-binding protein; Csaids binding protein; CSBP; CSBP1; CSBP2; CSPB1; cytokine suppressive anti-inflammatory drug binding protein; Cytokine suppressive anti-inflammatory drug-binding protein; ERK-6; ERK3; ERK6; EXIP; Extracellular signal-regulated kinase 6; MAP kinase 11; MAP kinase 12; MAP kinase 13; MAP kinase 14; MAP kinase MXI2; MAP kinase p38 alpha; MAP kinase p38 beta; MAP kinase p38 delta; MAP kinase p38 gamma; MAPK 11; MAPK 12; MAPK 13; MAPK 14; MAPK-13; MAPK11; MAPK12; MAPK13; MAPK14; MAX-interacting protein 2; MGC99536; Mitogen-activated protein kinase 11; Mitogen-activated protein kinase 12; Mitogen-activated protein kinase 13; Mitogen-activated protein kinase 14; mitogen-activated protein kinase 3; Mitogen-activated protein kinase p38 alpha; Mitogen-activated protein kinase p38 beta; Mitogen-activated protein kinase p38 delta; Mitogen-activated protein kinase p38 gamma; mitogen-activated protein kinase p38-2; MK11; MK12; MK13; MK14; MXI2; p38; p38 MAP kinase; p38 mitogen activated protein kinase; p38-2; p38-alpha; P38A; p38ALPHA; p38alpha Exip; p38b; p38Beta; P38BETA2; P38D; p38delta; P38G; P38GAMMA; PRKM11; PRKM12; PRKM13; PRKM14; PRKM15; RK; SAPK-3; SAPK2; SAPK2A; SAPK2B; SAPK3; SAPK4; Stress-activated protein kinase 2; stress-activated protein kinase 2A; Stress-activated protein kinase 2b; Stress-activated protein kinase 3; Stress-activated protein kinase 4; stress-activated protein kinase-2; stress-activated protein kinase-2b
